Aximad may be available in the countries listed below.
Cefotaxime sodium salt (a derivative of Cefotaxime) is reported as an ingredient of Aximad in the following countries:
International Drug Name Search
Class: Skin and Mucous Membrane Agents, Miscellaneous
VA Class: DE752
Chemical Name: 6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoic acid
Molecular Formula: C28H28O3
CAS Number: 106685-40-9
Brands: Differin
Retinoid; synthetic naphthoic acid-derivative.7 8 10 11 12 13 14 15 16 17 18 19 20 22
Treatment of acne vulgaris.1 4 5 6 7 11 12 13 14 16 17 18 19 20 21 22 31 32
Apply a thin film to skin as a cream, gel, or solution.1 4 5 7 11 12 13 16 17 18 19 20 21 22 31 32
Cleanse and dry the affected areas prior to application.1 31 32
Do not apply to eye(s), lips, angles of nose, or mucous membranes.1 31 32
A transient feeling of pruritus or burning may occur immediately after application.1 12 31 32 If increased sensitivity or irritation occurs, reduce frequency of application or, depending on the severity, discontinue use.1 31 32
Apparent exacerbation of acne that may occur during early weeks of therapy is attributable to the drug’s action on previously unseen lesions; do not discontinue.1 31 32
Excessive use does not increase therapeutic effects and may produce marked erythema, peeling, and discomfort.1 31 32
Remove single-use pledget applicators from foil immediately before use, use once, and then discard; do not use if seal is broken.31
Children and adolescents ≥12 years of age: Apply once daily in the evening at bedtime.1 12 31 32
Improvement usually detectable within 8–12 weeks.1 31 32
Apply once daily in the evening at bedtime.1 12 31 32
Improvement usually detectable within 8–12 weeks.1 31 32
Children and adolescents ≥12 years of age: most reported experience to date has been for treatment periods that did not exceed 12 weeks.4 5 6 12 22
Most reported experience to date has been for treatment periods that did not exceed 12 weeks.4 5 6 12 22
Known hypersensitivity to adapalene or any ingredient in the formulation.1 31 32
Increased risk for sunburn; minimize exposure to sunlight or artificial UV irradiation sources (e.g., sunlamps).1 31 32
Use caution in patients subjected to considerable occupational sun exposure or with inherent sun sensitivity; use of sunscreen products (SPF 15 or greater) and protective clothing over treated areas recommended when exposure cannot be avoided.1 31 32
Avoid concomitant use of photosensitizing agents.33 (See Interactions.)
Use not recommended in patients with sunburn until full recovery occurs.1 31
Discontinue therapy if sensitivity reaction or chemical irritation occurs.1 31 32
Erythema, dryness, scaling, burning, or pruritus may occur.1 31 32 If increased sensitivity or irritation occurs, use less frequently or, depending on the severity of the reaction, discontinue.1 31 32
Do not apply to cuts, abrasions, or eczematous or sunburned skin.1 31 32 (See Photosensitivity under Cautions.)
Use of mild or soapless cleanser is recommended; use medicated or drying soaps and abrasive soaps and cleansers with caution.1 31 32
Avoid use of irritating cosmetics, other preparations, or processes (e.g., electrolysis) that might dry or irritate the skin.33 (See Interactions.)
Possible increased skin irritation in patients exposed to environmental extremes (e.g., wind, cold).1 31 32
Use moisturizers if necessary; avoid preparations containing alpha hydroxy or glycolic acids.32
Category C.1 31 32
Not known whether adapalene is distributed into milk.1 31 32 Use caution.1 31 32
Safety and efficacy not established in children <12 years of age.1 31 32
Insufficient experience in controlled clinical studies in patients ≥65 years of age to determine whether geriatric patients respond differently to adapalene than younger adults.32 However, clinical experience generally has not revealed age-related differences.32
Erythema, scaling, dryness, pruritus, burning/stinging.1 31 32
Drug | Interaction | Comments |
|---|---|---|
Keratolytic agents (e.g., resorcinol, salicylic acid, sulfur) | Possible additive effects1 31 32 | Allow sufficient time for the effects of the keratolytic agent to subside before initiating adapalene1 31 32 |
Photosensitizing agents (e.g., fluoroquinolone anti-infectives, phenothiazines, sulfonamides, thiazide diuretics) | Possible increased phototoxicity33 | Avoid concomitant use33 |
Potential pharmacodynamic interaction (increased skin irritation).1 31 32 Avoid concurrent use of topical preparations with high concentrations of alcohol, menthol, spices, or lime (e.g., lotions, astringents, perfume); irritating cosmetics (e.g., toners, peeling [desquamating] agents); permanent wave solutions; or hair depilatories or waxes.1 31 32 33
Minimally absorbed following topical application.1 31 32
Eliminated principally by biliary excretion.1 31 32
20–25°C.1 31 32
Protect cream from freezing.32
Store solution upright in tight container.31
Actions similar to those of other retinoids (e.g., isotretinoin, tretinoin) but more potent anti-inflammatory activity in vitro and in vivo.1 4 5 6 9 13 15 16 17 19 23 24 31
Relatively selective affinity for specific nuclear retinoic acid receptor (RAR) proteins (e.g., RARβ, RARγ) that appear to enhance gene transcription.5 6 7 23 24
Exact mechanism(s) of action not elucidated.1 4 5 6 9 13 15 16 17 19 31 Appears to affect expression of genes that modulate follicular keratinization5 19 22 and cell (e.g., epithelial) differentiation,1 4 5 6 9 10 13 15 19 22 23 31 which result in inhibition of corneocyte accumulation and cohesion and reduction in inflammatory and noninflammatory acne lesions.1 6 11 12 22 23 24 31
Importance of clinicians instructing patients about proper use of the drug.1 31 32
Importance of continuing therapy in early weeks, even if acne initially appears to worsen.1 31 32
Risk of photosensitivity; importance of using sunscreens and wearing protective clothing over treated areas.1 31 32
Importance of avoiding contact with eyes, lips, angles of nose, or mucous membranes.1 31 32
Importance of not applying adapalene to cuts, abrasions, or eczematous or sunburned skin.1 31 32
Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.1 31 32
Importance of patients informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs.1 31 32
Importance of informing patients of other important precautionary information.1 31 32 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Topical | Cream | 0.1% | Differin (with parabens) | Galderma |
Gel | 0.1% | Differin (with methylparaben and propylene glycol) | Galderma | |
Pledgets (saturated with solution) | 0.1% | Differin (with SD alcohol 40-B 30% w/v) | Galderma | |
Solution | 0.1% | Differin (with SD alcohol 40-B 30% w/v) | Galderma |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Differin 0.1% Cream (GALDERMA): 45/$280 or 135/$829.96
Differin 0.1% Gel (GALDERMA): 45/$280 or 135/$829.96
Differin 0.3% Gel (GALDERMA): 45/$222 or 135/$630.01
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions February 2005. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Galderma. Differin (adapalene) gel 0.1% prescribing information. Fort Worth, TX; 1996 May.
2. Hurwitz S. Acne vulgaris: current concepts of pathogenesis and treatment. Am J Dis Child. 1979; 133:536-44. [PubMed 155397]
3. Chandraratna RAS. Tazarotene—first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996; 135:18-25.
4. Verschoore M, Langner A, Wolska H et al. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol. 1991; 124:368-71. [IDIS 280987] [PubMed 1827344]
5. Shalita A, Weiss JS, Chalker DK et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996; 34:482-5. [IDIS 364859] [PubMed 8609263]
6. Bernard BA. Adapalene, a new chemical entity with retinoid activity. Skin Pharmacol. 1993; 6(Suppl 1):61-9. [PubMed 8142113]
7. Griffiths CEM, Elder JT, Bernard BA et al. Comparison of CD271 (Adapalene) and all- trans retinoic acid in human skin: dissociation of epidermal effects and CRABP-II mRNA expression. J Invest Dermatol. 1993; 101:325-28. [PubMed 8396608]
8. Jamoulle JC, Grandjean L, Lamaud E et al. Follicular penetration and distribution of topically applied CD 271, a new naphthoic acid derivative intended for topical acne treatment. J Invest Dermatol. 1990; 94:731-2. [PubMed 2139085]
9. Hensby C, Cavey D, Bouclier M et al. The in vivo and in vitro anti- inflammatory activity of CD271: a new retinoid-like modulator of cell differentiation. Agents Actions. 1990; 29:56-8. [PubMed 2109510]
10. Bernerd F, Ortonne JP, Bouclier M et al. The rhino mouse model: the effects of topically applied all-trans retinoic acid and CD271 on the fine structure of the epidermis and utricle wall of pseudocomedones. Arch Dermatol Res. 1991; 283:100-7. [PubMed 2069410]
11. Leyden JJ. Therapy for acne vulgaris. N Engl J Med. 1997; 336:1156-62. [IDIS 388309] [PubMed 9099661]
12. Brogden RN, Goa KL. Adapalene: a review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs. 1997; 53:511-9. [PubMed 9074847]
13. Verschoore M. Adapalene: a novel topical retinoid receptor agonist for acne—overview. J Am Acad Dermatol. 1997; 36:S91.
14. Kligman AM. The treatment of acne with topical retinoids: one man’s opinions. J Am Acad Dermatol. 1997; 36:S92-5.
15. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997; 36:S96-103. [PubMed 9204085]
16. Verschoore M, Poncet M, Czernielewski J et al. Adapalene 0.1% gel has low skin- irritation potential. J Am Acad Dermatol. 1997; 36:S104-9.
17. Caron D, Sorba V, Kerrouche N et al. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol. 1997; 36:S110-12. [IDIS 389401] [PubMed 9204087]
18. Caron D, Sorba V, Clucas A et al. Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol. 1997; 36:S113-5.
19. Clucas A, Verschoore M, Sorba V et al. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. J Am Acad Dermatol. 1997; 36:S116-8.
20. Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol. 1997; 36:S119-25. [PubMed 9204090]
21. Cunliffe WJ, Caputo R, Dreno B et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol. 1997; 36:S126-34. [IDIS 389404] [PubMed 9204091]
22. Anon. Adapalene for acne. Med Lett Drugs Ther. 1997; 39:19-20. [PubMed 9057779]
23. Thiboutot DM. Acne: an overview of clinical research findings. Dermatol Clin. 1997; 15:97-109. [PubMed 9001864]
24. Gibson JR. Rationale for the development of new topical treatments for acne vulgaris. Cutis. 1996; 57:13-9. [PubMed 8654127]
25. Anon. Update on birth defects with isotretinoin. FDA Drug Bull. 1984; 14:15-6. [PubMed 6592122]
26. Benke PJ. The isotretinoin teratogen syndrome. JAMA. 1984; 251:3267-9. [IDIS 186330] [PubMed 6587131]
27. de la Cruz E, Sun S, Vangvanichyakorn K et al. Multiple congenital malformations associated with maternal isotretinoin therapy. Pediatrics. 1984; 74:428-30. [IDIS 189774] [PubMed 6591112]
28. Lammer EJ, Chen DT, Hoar RM et al. Retinoic acid embryopathy. N Engl J Med. 1985; 313:837-41. [IDIS 204599] [PubMed 3162101]
29. Rosa FW, Wilk AL, Kelsey FO. Teratogen update: vitamin A congeners. Teratology. 1986; 33:355-64. [PubMed 3461576]
30. Cohen M, Rubenstein A, Li JK et al. Thymic hypoplasia associated with isotretinoin embryopathy. Am J Dis Child. 1987; 141:263-6. [IDIS 226304] [PubMed 3492909]
31. Galderma. Differin (adapalene) solution 0.1% prescribing information. Fort Worth, TX; 1997 Jul.
32. Galderma Laboratories. Differin cream 0.1% (adapalene) prescribing information. Fort Worth, TX; 2000 May.
33. Galderma Laboratories, Fort Worth, TX: Personal Communication.
Treating outer and some middle ear infections. It may also be used for other conditions as determined by your doctor.
Floxin Otic Solution is a fluoroquinolone antibiotic. It works by killing the bacteria.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Floxin Otic Solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Floxin Otic Solution. However, no specific interactions with Floxin Otic Solution are known at this time.
Ask your health care provider if Floxin Otic Solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Floxin Otic Solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Floxin Otic Solution.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Itching of the ear; taste changes.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); decreased hearing; ear irritation; hearing loss; redness, bleeding, or swelling.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Floxin Otic side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Floxin Otic Solution may be harmful if swallowed.
Store Floxin Otic Solution at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Floxin Otic Solution out of the reach of children and away from pets.
This information is summary only. It does not contain all information about Floxin Otic Solution. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Céfixime Arrow may be available in the countries listed below.
Cefixime trihydrate (a derivative of Cefixime) is reported as an ingredient of Céfixime Arrow in the following countries:
International Drug Name Search
Tikosyn may cause new irregular heart rhythms (arrhythmias). To reduce this risk, it is recommended that you stay in a facility with appropriate monitoring equipment for at least the first 3 days of therapy.
Maintaining normal heart rhythm in patients with certain irregular heart rhythms. It may also be used for other conditions as determined by your doctor.
Tikosyn is an antiarrhythmic. It works by blocking certain heart currents, which allows the heart to regain a normal rhythm.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Tikosyn. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Tikosyn. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Tikosyn may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Tikosyn as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Tikosyn.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dizziness; headache; nausea; respiratory tract infection.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; dark urine; difficulty breathing; fast, slow, or irregular heartbeat; fainting; heart attack; pale stool; paralysis; pounding in the chest; stopping of the heart; sudden death; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Tikosyn side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Tikosyn at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tikosyn out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Tikosyn. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Generic Name: tretinoin topical (TRET in oin)
Brand Names: Altinac, Atralin, Avita, Renova, Retin A Micro Gel, Retin-A, Tretin-X
Tretinoin is a topical (applied to the skin) form of vitamin A that helps the skin renew itself.
The Retin-A and Avita brands of tretinoin are used to treat acne. The Renova brand of tretinoin is used to reduce the appearance of fine wrinkles and mottled skin discoloration, and to make rough facial skin feel smoother.
Tretinoin topical may also be used for other purposes not listed in this medication guide.
Use tretinoin topical exactly as your doctor has prescribed it for you. Using more medicine or applying it more often than prescribed will not make it work any faster, and may increase side effects. Do not use this medication for longer than your doctor has prescribed.
Applying tretinoin topical to wet skin may cause skin irritation. If you use Renova, wait at least 20 minutes after washing your face before applying a thin layer of the medication.
Do not wash the treated area for at least 1 hour after applying tretinoin topical. Avoid the use of other skin products on the treated area for at least 1 hour following application of tretinoin topical.
Applying an excessive amount of tretinoin gel may result in "pilling" of the medication. If this occurs, use a thinner layer of gel with the next application.
Tretinoin topical should be used as part of a complete skin care program that includes avoiding sunlight and using an effective sunscreen and protective clothing.
Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and wait until your next regularly scheduled dose. Do not apply extra medicine to make up the missed dose.
Avoid using skin products that can cause irritation, such as harsh soaps, shampoos, or skin cleansers, hair coloring or permanent chemicals, hair removers or waxes, or skin products with alcohol, spices, astringents, or lime. Do not use other medication skin products unless your doctor has told you to.
Your skin may be more sensitive to weather extremes such as cold and wind while using this medicine.
Less serious side effects may include burning, warmth, stinging, tingling, itching, redness, swelling, dryness, peeling, irritation, or discolored skin.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following drugs can interact with tretinoin topical, which can make your skin more sensitive to natural and artificial sunlight. Before using this medication, tell your doctor if you are using any of these:
a diuretic (water pill);
tetracycline (Sumycin, Panmycin, Robitet), minocycline (Minocin), doxycycline (Doryx, Vibramycin), demeclocycline (Declomycin), and others;
an antibiotic such as ciprofloxacin (Cipro), ofloxacin (Floxin), and others;
a sulfa drug such as Bactrim, Septra, Cotrim, and others; or
chlorpromazine (Thorazine), prochlorperazine (Compazine), fluphenazine (Permitil, Prolixin), promethazine (Phenergan, Promethegan), perphenazine (Trilafon), and others.
This list is not complete and there may be other drugs that can affect tretinoin topical. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
See also: Altinac side effects (in more detail)
Ceforal may be available in the countries listed below.
Cefadroxil is reported as an ingredient of Ceforal in the following countries:
Cefalexin monohydrate (a derivative of Cefalexin) is reported as an ingredient of Ceforal in the following countries:
International Drug Name Search
